Clinical and molecular genetic analysis of cytologically uncertain thyroid nodules in patients with thyroid disease

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023761%3A_____%2F25%3AN0000001" target="_blank" >RIV/00023761:_____/25:N0000001 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/25:10472986 RIV/00216208:11120/25:43926448 RIV/00216208:11140/25:10472986 RIV/00064173:_____/25:43926448 and 3 more

Result on the web

<a href="https://doi.org/10.5507/bp.2023.048" target="_blank" >https://doi.org/10.5507/bp.2023.048</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2023.048" target="_blank" >10.5507/bp.2023.048</a>

Result language

angličtina

Original language name

Clinical and molecular genetic analysis of cytologically uncertain thyroid nodules in patients with thyroid disease

Original language description

Background. The current requirement is to establish the preoperative diagnosis accurately as possible and to achieve an adequate extent of surgery. The aim of this study was to define the preoperative clinical and molecular genetic risks of malignancy in indeterminate thyroid nodules (Bethesda III and IV) and to determine their impact on the surgical strategy.Methods. Prospectively retrospective analysis of 287 patients provided the basis of preoperative laboratory examination, sonographic stratification of malignancy risks and cytological findings. Molecular tests focused on pathogenic variants of genes associated with thyroid oncogenesis in cytologically indeterminate nodules (Bethesda III and IV). The evaluation included clinical risk factors: positive family history, radiation exposure and growth in size and/or number of nodules.Results. Preoperative FNAB detected 52 cytologically indeterminate nodules (28.7%) out of 181 patients. Postoperative histopathological examination revealed malignancy in 12 cases (23.7%) and there was no significant difference between Bethesda III and IV categories (P=0.517). Clinical risk factors for malignancy were found in 32 patients (61.5%) and the presence of at least one of them resulted in a clearly higher incidence of malignancy than their absence (31.3% vs. 10.0%, respectively). Pathogenic variants of genes were detected in 12/49 patients in Bethesda III and IV, and in 4 cases (33.3%) thyroid carcinoma was revealed. The rate of malignancies was substantially higher in patients with pathogenic variants than in those without (33.3% vs. 16.2%, respectively).Conclusions. Our experience implies that molecular genetic testing is one of several decision factors. We will continue to monitor and enlarge our patient cohort to obtain long-term follow-up data.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30204 - Oncology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Biomedical Papers

ISSN

1213-8118

e-ISSN

1804-7521

Volume of the periodical

169

Issue of the periodical within the volume

1

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

6

Pages from-to

26-31

UT code for WoS article

001121310600001

EID of the result in the Scopus database

2-s2.0-86000744372